GJA1 and breast cancer: Previously it was shown in non-breast cancer cell types that the therapeutic peptide mimetic ACT1, which targets Cx43 protein interaction and/or signaling, is able to increase gap junction hemichannel recruitment and size, thereby stabilizing gap junction intercellular communication without altering Cx43 levels [33,34].